Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LASN01 in Thyroid Eye Disease
2023-508161-32-00Phase 2Completed
- Sponsor
- Lassen Therapeutics
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in Graves Orbitopathy (GO) comparing LASN01 with Placebo (2 arms). Primary endpoints: Change in proptosis in the study eye and Safety and tolerability of LASN01. Started Mar 2024; status: completed.
02
Drugs
LASN01
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on 2023-508161-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508161-32-00.